Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Research across Cancer
Related studies from across the Cancer family.
Liquid biopsy guides kidney-sparing decisions in upper tract urothelial carcinoma without replacing standard care
Liquid biopsy helps doctors decide on kidney-sparing care for upper tract urothelial carcinoma
This review discusses liquid biopsy-guided kidney-sparing management for patients with upper tract urothelial carcinoma. The authors note th…
A review shows liquid biopsy adds value to kidney-sparing decisions for upper tract urothelial carcinoma but does not replace standard imagi…
Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Meta-analysis finds 3.2% prevalence of germline MMR mutations in patients with upper tract urothelial carcinoma
Study finds 3.2% of upper tract urothelial cancer patients have inherited DNA repair mutations
A systematic review and meta-analysis of 14 studies including 2378 patients with upper tract urothelial carcinoma (UTUC) found a pooled prev…
About 3% of upper tract urothelial cancer patients carry inherited DNA repair mutations that link their cancer to Lynch syndrome and affect …
Self-expandable metal stents improve patency and survival in malignant hilar biliary obstruction
Which stent helps people with blocked bile ducts live longer?
A meta-analysis of individual patient data from 5 RCTs (322 patients) found that self-expandable metal stents (SEMSs) significantly improved…
Metal stents help people with blocked bile ducts live longer and avoid repeat procedures compared to plastic tubes, according to new analysi…
Renal pelvis tumors show survival advantage over other UTUC sites in NCDB analysis
Study finds kidney pelvis tumors linked to better survival in urinary tract cancer
A retrospective cohort study of 12,300 patients with upper urinary tract urothelial carcinoma from the National Cancer Database found renal …
Patients with kidney pelvis tumors had better survival than those with tumors in other upper urinary tract locations, based on analysis of o…
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …